AlphaMaven AlphaMaven
Venture Capital

Abby Care Lands $82 Million in Series C

Reported by Vcnewsdaily
Oct 19, 2026· 1 min read
Save Post LinkedIn Email
Key Takeaways
  • • Abby Care, an AI-powered care-at-home platform that trains and certifies family members as paid caregivers, raised $82 million in Series C financing, according to the company's announcement on October 19, 2026.
  • • Transformation Capital led the round, with new investors CVS Health Ventures, Frist Cressey Ventures, and Pivotal Ventures participating alongside existing backers Khosla Ventures, Thrive Capital, and Sequoia Capital.
  • • The round brings in a healthcare-focused strategic investor in CVS Health Ventures, signaling interest in home-based caregiving as a care delivery model.
Summary
Abby Care, a San Francisco-based company, announced that it has raised $82 million in Series C financing, according to a company announcement reported by Massinvestor on October 19, 2026. The company operates an AI-powered care-at-home platform that enables family members to become trained, certified paid caregivers for relatives who need care.

Transformation Capital led the latest round. New investors CVS Health Ventures, Frist Cressey Ventures, and Pivotal Ventures joined the round, while existing investors Khosla Ventures, Thrive Capital, and Sequoia Capital also participated. The participation of CVS Health Ventures, the venture arm of the CVS Health healthcare group, points to strategic interest from the healthcare sector in home-based caregiving services.

The primary source does not disclose the valuation, revenue, customer count, or the specific use of proceeds from the financing.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Vcnewsdaily Abby Care Lands $82 Million in Series C

Not a member yet?

Why AlphaMaven

The Alternative Investment
Intelligence Platform

Access nearly 1 million industry profiles in alternative investments — firms, funds, decision-makers and regulatory filings.

Start a free 7-day trial — card required, cancel anytime
Data · Intelligence · ROI
Company, fund & contact directory
Screener with filters & saved searches
Regulatory data — SEC, NFA, GLEIF, Form D
Manager-reported fund performance
11K+ members contributing data
Daily news with AI executive summaries
Data exports from your tracked list
Research guides, leaderboards & glossary
168,000+
Firms
594,900+
Decision-Makers
70,000+
Data Sources
Start your free 7-day trial

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.